MedMira Inc. (MIR.V)
CAD 0.09
(-10.53%)
CAD 0.09
(-10.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.67 Million CAD | -46.09% |
| 2022 | -1.83 Million CAD | -171.02% |
| 2021 | -675.79 Thousand CAD | 66.96% |
| 2020 | -2.04 Million CAD | 2.9% |
| 2019 | -2.1 Million CAD | 16.06% |
| 2018 | -2.5 Million CAD | 5.7% |
| 2017 | -2.66 Million CAD | 48.41% |
| 2016 | -5.15 Million CAD | -59.72% |
| 2015 | -3.22 Million CAD | 15.79% |
| 2014 | -3.83 Million CAD | -853.35% |
| 2013 | -402.3 Thousand CAD | -111.93% |
| 2012 | 3.37 Million CAD | 168.93% |
| 2011 | -4.89 Million CAD | -10.72% |
| 2010 | -4.41 Million CAD | 16.05% |
| 2009 | -5.26 Million CAD | 25.01% |
| 2008 | -7.01 Million CAD | -11.62% |
| 2007 | -6.28 Million CAD | 13.72% |
| 2006 | -7.28 Million CAD | -19.34% |
| 2005 | -6.1 Million CAD | -52.94% |
| 2004 | -3.99 Million CAD | 13.5% |
| 2003 | -4.61 Million CAD | 18.42% |
| 2002 | -5.65 Million CAD | 21.38% |
| 2001 | -7.19 Million CAD | -148.39% |
| 2000 | -2.89 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -590.78 Thousand CAD | 24.29% |
| 2024 Q1 | -780.36 Thousand CAD | 18.94% |
| 2024 Q3 | -780.14 Thousand CAD | -32.05% |
| 2023 FY | -2.67 Million CAD | -46.09% |
| 2023 Q3 | -589.98 Thousand CAD | -20.28% |
| 2023 Q4 | -962.71 Thousand CAD | -63.18% |
| 2023 Q2 | -490.5 Thousand CAD | 22.44% |
| 2023 Q1 | -632.44 Thousand CAD | -36.55% |
| 2022 Q2 | -468.34 Thousand CAD | 4.23% |
| 2022 Q1 | -489 Thousand CAD | 23.23% |
| 2022 FY | -1.83 Million CAD | -171.02% |
| 2022 Q4 | -463.15 Thousand CAD | -12.67% |
| 2022 Q3 | -411.06 Thousand CAD | 12.23% |
| 2021 Q3 | -338.05 Thousand CAD | 18.72% |
| 2021 Q1 | 715.17 Thousand CAD | 364.95% |
| 2021 Q2 | -415.93 Thousand CAD | -158.16% |
| 2021 Q4 | -636.98 Thousand CAD | -88.43% |
| 2021 FY | -675.79 Thousand CAD | 66.96% |
| 2020 Q2 | -614.3 Thousand CAD | -31.07% |
| 2020 Q4 | -269.92 Thousand CAD | 61.02% |
| 2020 Q1 | -468.67 Thousand CAD | -4.49% |
| 2020 Q3 | -692.47 Thousand CAD | -12.73% |
| 2020 FY | -2.04 Million CAD | 2.9% |
| 2019 Q1 | -550.03 Thousand CAD | -9.43% |
| 2019 FY | -2.1 Million CAD | 16.06% |
| 2019 Q2 | -595.32 Thousand CAD | -8.23% |
| 2019 Q3 | -512.55 Thousand CAD | 13.9% |
| 2019 Q4 | -448.53 Thousand CAD | 12.49% |
| 2018 FY | -2.5 Million CAD | 5.7% |
| 2018 Q1 | -636.17 Thousand CAD | -14.03% |
| 2018 Q3 | -656.77 Thousand CAD | 8.0% |
| 2018 Q2 | -713.85 Thousand CAD | -12.21% |
| 2018 Q4 | -502.66 Thousand CAD | 23.47% |
| 2017 Q4 | -557.88 Thousand CAD | 25.79% |
| 2017 Q2 | -549.6 Thousand CAD | 31.45% |
| 2017 FY | -2.66 Million CAD | 48.41% |
| 2017 Q1 | -801.8 Thousand CAD | 61.11% |
| 2017 Q3 | -751.76 Thousand CAD | -36.78% |
| 2016 Q1 | -900.41 Thousand CAD | -201.84% |
| 2016 Q4 | -2.06 Million CAD | -69.82% |
| 2016 Q3 | -1.21 Million CAD | -23.68% |
| 2016 FY | -5.15 Million CAD | -59.72% |
| 2016 Q2 | -981.73 Thousand CAD | -9.03% |
| 2015 Q1 | -1.04 Million CAD | -189.03% |
| 2015 FY | -3.22 Million CAD | 15.79% |
| 2015 Q4 | -298.31 Thousand CAD | 64.99% |
| 2015 Q3 | -852.04 Thousand CAD | 17.81% |
| 2015 Q2 | -1.03 Million CAD | 0.56% |
| 2014 Q1 | -839.35 Thousand CAD | -10.63% |
| 2014 FY | -3.83 Million CAD | -853.35% |
| 2014 Q2 | -1.41 Million CAD | -68.86% |
| 2014 Q3 | -1.21 Million CAD | 14.07% |
| 2014 Q4 | -360.69 Thousand CAD | 70.39% |
| 2013 Q3 | -859.68 Thousand CAD | -180.06% |
| 2013 Q1 | 142.35 Thousand CAD | -98.26% |
| 2013 FY | -402.3 Thousand CAD | -111.93% |
| 2013 Q2 | 1.07 Million CAD | 654.28% |
| 2013 Q4 | -758.7 Thousand CAD | 11.75% |
| 2012 Q4 | 8.16 Million CAD | 607.34% |
| 2012 Q3 | -1.6 Million CAD | 33.37% |
| 2012 FY | 3.37 Million CAD | 168.93% |
| 2012 Q1 | -1.84 Million CAD | -15.82% |
| 2012 Q2 | -2.41 Million CAD | -30.79% |
| 2011 Q1 | -1.11 Million CAD | 37.03% |
| 2011 Q2 | -1.3 Million CAD | -17.36% |
| 2011 Q3 | -881.32 Thousand CAD | 32.44% |
| 2011 FY | -4.89 Million CAD | -10.72% |
| 2011 Q4 | -1.59 Million CAD | -80.97% |
| 2010 Q1 | -1.07 Million CAD | 20.02% |
| 2010 FY | -4.41 Million CAD | 16.05% |
| 2010 Q2 | -956.68 Thousand CAD | 10.84% |
| 2010 Q3 | -623.89 Thousand CAD | 34.79% |
| 2010 Q4 | -1.76 Million CAD | -182.91% |
| 2009 Q4 | -1.34 Million CAD | -37.33% |
| 2009 Q2 | -1.19 Million CAD | 31.63% |
| 2009 Q1 | -1.74 Million CAD | 50.51% |
| 2009 FY | -5.26 Million CAD | 25.01% |
| 2009 Q3 | -976.93 Thousand CAD | 18.3% |
| 2008 FY | -7.01 Million CAD | -11.62% |
| 2008 Q3 | -1.37 Million CAD | -117.7% |
| 2008 Q2 | -632.63 Thousand CAD | 57.1% |
| 2008 Q1 | -1.47 Million CAD | 30.82% |
| 2008 Q4 | -3.53 Million CAD | -156.57% |
| 2007 Q4 | -2.13 Million CAD | -82.78% |
| 2007 Q3 | -1.16 Million CAD | 22.86% |
| 2007 Q2 | -1.51 Million CAD | -2.27% |
| 2007 Q1 | -1.47 Million CAD | 31.57% |
| 2007 FY | -6.28 Million CAD | 13.72% |
| 2006 Q2 | -1.16 Million CAD | 33.44% |
| 2006 Q1 | -1.75 Million CAD | 21.26% |
| 2006 Q3 | -2.2 Million CAD | -88.71% |
| 2006 Q4 | -2.16 Million CAD | 2.02% |
| 2006 FY | -7.28 Million CAD | -19.34% |
| 2005 Q4 | -2.22 Million CAD | -69.18% |
| 2005 Q3 | -1.31 Million CAD | 5.08% |
| 2005 Q2 | -1.38 Million CAD | -18.42% |
| 2005 Q1 | -1.17 Million CAD | -24.96% |
| 2005 FY | -6.1 Million CAD | -52.94% |
| 2004 Q2 | -996.33 Thousand CAD | -7.66% |
| 2004 Q3 | -1.13 Million CAD | -13.7% |
| 2004 Q1 | -925.45 Thousand CAD | -28.99% |
| 2004 FY | -3.99 Million CAD | 13.5% |
| 2004 Q4 | -938.03 Thousand CAD | 17.2% |
| 2003 Q1 | -1.05 Million CAD | 57.13% |
| 2003 FY | -4.61 Million CAD | 18.42% |
| 2003 Q2 | -1.14 Million CAD | -8.66% |
| 2003 Q3 | -1.69 Million CAD | -48.05% |
| 2003 Q4 | -717.48 Thousand CAD | 57.72% |
| 2002 Q3 | -1.09 Million CAD | -18.51% |
| 2002 Q1 | -1.18 Million CAD | 0.0% |
| 2002 Q4 | -2.46 Million CAD | -124.97% |
| 2002 FY | -5.65 Million CAD | 21.38% |
| 2002 Q2 | -923.08 Thousand CAD | 21.78% |
| 2001 FY | -7.19 Million CAD | -148.39% |
| 2000 FY | -2.89 Million CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.32 Million CAD | 19.571% |
| Covalon Technologies Ltd. | -4.46 Million CAD | 40.021% |
| Hemostemix Inc. | -2.5 Million CAD | -6.936% |
| Universal Ibogaine Inc. | -10.49 Million CAD | 74.508% |
| Kane Biotech Inc. | -5.03 Million CAD | 46.849% |
| Marvel Biosciences Corp. | -2.29 Million CAD | -16.77% |
| NervGen Pharma Corp. | -22.38 Million CAD | 88.046% |
| XORTX Therapeutics Inc. | -2.85 Million CAD | 6.425% |